Journal List > Yonsei Med J > v.50(3) > 1030485

TOOLS
Park, Sohn, Jeong, Sung, Shin, Lee, and Chung: Inhibitory Effect of Fentanyl on Phenylephrine-Induced Contraction of the Rat Aorta
Original Article
Yonsei Medical Journal

Yonsei Medical Journal 2009; 50(3): 414-421.

Published online: 24 June 2009

DOI: https://doi.org/10.3349/ymj.2009.50.3.414

Inhibitory Effect of Fentanyl on Phenylephrine-Induced Contraction of the Rat Aorta

Kyeong-Eon Park1, Ju-Tae Sohn1, 2, Young Seok Jeong1, Hui-Jin Sung1, Il-Woo Shin1, Heon-Keun Lee1, Young-Kyun Chung1

1Department of Anesthesiology and Pain Medicine, Gyeongsang National University School of Medicine, Jinju, Korea.

2Institutes of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea.

Corresponding author: Dr. Ju-Tae Sohn, Department of Anesthesiology and Pain Medicine, Gyeongsang National University Hospital, 90 Chilam-dong, Jinju 660-702, Korea. Tel: 82-55-750-8586, Fax: 82-55-750-8142, jtsohn@nongae.gsnu.ac.kr

Received 16 July 2008       Revised 3 October 2008       Accepted 3 October 2008

© Copyright: Yonsei University College of Medicine 2009

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

Fentanyl was reported to inhibit the α1-adrenoceptor agonist-induced contraction. The goal of this in vitro study was to identify the α1-adrenoceptor subtype primarily involved in the fentanyl-induced attenuation of phenylephrine-induced contraction in isolated endothelium-denuded rat aorta.

Materials and Methods

Aortic rings were suspended in order to record isometric tension. Concentration-response curves for phenylephrine (10-9 to 10-5 M) were generated in the presence or absence of one of the following drugs: fentanyl (3×10-7, 10-6, 3×10-6 M), 5-methylurapidil (3×10-8, 10-7, 3×10-7 M), chloroethylclonidine (10-5 M) and BMY 7378 (3×10-9, 10-8, 3×10-8 M). Phenylephrine concentration-response curves were generated in the presence or absence of fentanyl in rings pretreated with either 3×10-9 M prazosin, 10-9 M 5-methylurapidil or 3×10-9 M BMY 7378.

Results

Fentanyl (10-6, 3×10-6 M) attenuated phenylephrine-induced contraction in the rat aorta. 5-Methylurapidil and BMY 7378 produced a parallel rightward shift in the phenylephrine concentration-response curve. The pA2 values for 5-methylurapidil and BMY 7378 were estimated to be 7.71 ± 0.15 and 8.99 ± 0.24, respectively. Fentanyl (10-6 M) attenuated phenylephrine-induced contraction in rings pretreated with 10-9 M 5-methylurapidil, but did not alter the rings when pretreated with 3×10-9 M BMY 7378. Pretreatment of the rings with chloroethylclonidine showed a 72.9 ± 2.3% reduction in phenylephrine-induced maximal contraction.

Conclusion

The results suggest that fentanyl attenuates phenylephrine-induced contraction by inhibiting the pathway involved in the α1D-adrenoceptor-mediated contraction of the rat aorta.

Keywords: Fentanyl, phenylephrine, 5-methylurapidil, BMY 7378, prazosin, rat aorta

INTRODUCTION

High-dose fentanyl has been widely used as a general anesthetic for patients undergoing heart surgery. Fentanyl administered intravenously at the clinical dose (4.5 µg/kg) has been shown to slightly decrease systemic blood pressure and vascular resistance, whereas high doses (40-160 µg/kg) have been shown to significantly decrease mean peripheral blood pressure.1,2 In addition, the hypotension produced by high-dose fentanyl (75 µg/kg) is associated with an increased need for the use of alpha-adrenergic agonists to maintain blood pressure.3 Fentanyl has been shown to inhibit the α1-adrenoceptor agonist-induced contraction in isolated aorta and pulmonary arteries.4-6
The α1-adrenoceptors are a heterogeneous group of receptors and, based on radioligand binding, molecular biology and isolated tissue experiments, they have been classified into three subtypes: the α1A-, α1B- and α1D-adrenoceptors for native receptors.7 All three subtypes of the α1-adrenoceptors have a high affinity for the non-subtype-selective α1-adrenoceptor antagonist prazosin,7 and are expressed in vascular smooth muscles, including the rat aorta.8 These subtypes can be identified by selective and non-selective antagonists. For example, 5-methyl-urapidil (5-MU) has a 10 to 50 times higher affinity for α1A-adrenoceptors, and the affinity of BMY 7378 for α1D-adrenoceptors is at least 100-fold higher.8 Chloroethylclo-nidine (CEC) is an irreversible antagonist that preferentially inactivates α1B-adrenoceptors, but it can also partially inactivate α1D-adrenoceptors.8 The α1D-adrenoceptors mediate the phenylephrine-induced contraction of the rat abdominal aorta, thoracic aorta, and mesenteric artery,9,10 and α1B-adrenoceptors mediate the phenylephrine-induced contraction of the human umbilical vein and canine pulmonary artery, as well as phenylephrine-induced contraction in the dog aorta.6,11,12 However, to the best of our knowledge, the α1-adrenoceptor subtype that is involved in the fentanyl-induced attenuation of the phenylephrine contraction-response curve in systemic circulation such as rat aortas has not yet been identified. The goals of the current in vitro study were to identify the α1-adrenoceptor subtype that is involved mainly in the fentanyl-induced attenuation of phenylephrine-induced contraction in isolated endothelium-denuded rat aorta and to characterize the α1-adrenoceptor subtype that is functionally important in mediating the contractile response to phenylephrine.

MATERIALS AND METHODS

All experimental procedures and protocols were approved by the Institutional Animal Care and Use Committee. Sprague-Dawley male rats, weighing 250-350 g each, were anesthetized by the intraperitoneal administration of pentobarbital sodium (50 mg/kg). The descending thoracic aorta was dissected free, and the surrounding connective tissue and fat were removed under microscopic guidance while the blood vessels were bathed in Krebs solution of the following composition: 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2.4 mM CaCl2, 25 mM NaHCO3, 11 mM glucose and 0.03 mM EDTA. The aorta was then cut into 2.5-mm rings, which were suspended on Grass isometric transducers (FT-03, Grass Instrument, Quincy, MA, USA) with a 2.0 g resting tension in 10 mL temperature-controlled baths (37℃) containing the Krebs solution, which was continuously gassed with 95% O2 and 5% CO2. The rings were equilibrated at a 2.0 g resting tension for 120 min, during which time the bathing solution was changed every 15 min. In all rings, the endothelium was intentionally removed by inserting a 25-G needle tip into the lumen of the rings and gently rolling the rings for a few seconds. The contractile response induced by isotonic 60 mM KCl was measured in each of the aortic rings.

Experimental protocol

The first series of these experiments was aimed at assessing the effect of fentanyl on contractile response induced by the α1-adrenoceptor agonist phenylephrine in endothelium-denuded rings. Fentanyl was added directly to the organ bath 30 min before cumulative phenylephrine-induced contraction. The effect of fentanyl on the concentration-response curves for phenylephrine (10-9 to 10-5 M) was assessed by comparing the contractile response in the presence or absence of fentanyl (3×10-7, 10-6, 3×10-6 M).
The second series of experiments was designed to determine which subtype of α1-adrenoceptor is functionally important in mediating phenylephrine-induced contraction in endothelium-denuded rat aorta. The effect of subtype-selective α1-adrenoceptor antagonists (α1A-adrenoceptor antagonist: 3×10-8, 10-7, 3×10-7 M 5-MU; α1D-adrenoceptor antagonist: 3×10-9, 10-8, 3×10-8 M BMY 7378) on the concentration-response curve for phenylephrine was assessed by comparing each contractile response in the presence and absence of each subtype-selective α1-adrenoceptor antagonist. The incubation period for each subtype-selective α1-adrenoceptor antagonist was 30 min before phenylephrine-induced contraction.
The third series of experiments was designed to assess the effect of the irreversible α1B-adrenoceptor antagonist CEC on the concentration-response curve for phenylephrine. The first concentration-response curve for phenylephrine was constructed before pretreatment with 10-5 M CEC. After being washed, aortic rings were exposed to CEC (10-5 M) for a period of 20 min. Following removal of the CEC by exchanges of the Krebs solution every 10 min for 1 hour, a second concentration-response curve for phenylephrine was constructed.
In the fourth series of experiments, the α1-adrenoceptor subtype dependence of fentanyl-induced attenuation of the contractile response induced by phenylephrine was examined. The effect of fentanyl (10-6 M) on the concentration-response curve for phenylephrine in the rings which had been pretreated with either 10-9 M 5-MU or 3×10-9 M BMY 7378 was assessed by comparing the contractile response in the presence and absence of fentanyl (10-6 M). In addition, the role of the α1-adrenoceptor in the fentanyl-induced attenuation of the contractile response induced by phenylephrine was assessed by examining the phenylephrine (10-9 to 10-4 M) concentration-response curve after prazosin (3×10-9 M) was added directly to organ bath, either alone or in combination with fentanyl (3×10-6 M). The incubation period for the subtype-selective or non-subtype-selective α1-adrenoceptor antagonists (3×10-9 M prazosin, 10-9 M 5-MU and 3×10-9 M BMY 7378) plus fentanyl (10-6, 3×10-6 M) or α1-adrenoceptor antagonist (subtype-selective or non-subtype-selective) alone was 30 min before the phenylephrine-induced contraction.

Drug and solution

All drugs used in the present study were of the highest purity commercially available and included phenylephrine HCl, acetylcholine, prazosin, 5-MU, CEC, BMY 7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro [4.5]decane-7,9-dione dihydrochloride) (Sigma Chemical, St. Louis, MO, USA), and fentanyl (Hana Pharmaceutical Co., Ltd., Seoul, Korea). All concentrations are expressed as the final molar concentration in the organ bath. All drugs were dissolved in distilled water.

Data analysis

The values are expressed as means ± SD. Contractile responses to phenylephrine are expressed as a percentage of their own maximum contraction to isotonic 60 mM KCl. The first and second phenylephrine-induced contractions are expressed as a percentage of the maximum obtained from the first phenylephrine concentration-response curve. The logarithm of the drug concentration (ED50), eliciting 50% of the maximum contractile response, was calculated using nonlinear regression analysis by fitting the concentration-response relation for phenylephrine to a sigmoidal curve, by using commercially available software (Prism version 3.02: GraphPad software, San Diego, CA, USA). Data were fitted to a sigmoidal dose-response curve using the following algorithm Y = Bottom + (Top - Bottom)/(1 + 10^ ((LogED50 - X) × Hill Slope)). The concentration ratio (CR) is defined as the concentration of agonist required to induce 50% maximal contractile response in the presence of antagonist divided by the agonist concentration that elicits the same degree of response in the absence of antagonist. The pA2 value represents the concentration of antagonists necessary to displace the concentration-response curve of an agonist by twofold. Subtype-selective α1-adrenoceptor antagonist pA2 values (-log M) were calculated from Arunlakshana and Schild plots and were obtained from the X-intercept of the plot of log (CR-1) against log molar antagonist concentration, where the slope was not different from unity.13 The slope and pA2 values calculated from Arunlakshana and Schild plots are expressed as mean ± SEM.13 Statistical analysis was performed using Student's t-test for paired comparison. One-way analysis of variance, followed by Tukey's multiple comparison, was used to compare more than two means. The p value < 0.05 was considered significant. N refers to the number of rats whose descending thoracic aortic rings were used in each experiment. Each group contained at least two rings from the same rat.

RESULTS

Fentanyl (3×10-7 M) did not significantly alter the phenylephrine concentration-response curve (Fig. 1). However, higher concentration of fentanyl (10-6, 3×10-6 M) significantly attenuated (p < 0.05 versus no drug) phenylephrine-induced contraction (ED50: no drug; -8.41 ± 0.34 versus 10-6 M fentanyl; -7.84 ± 0.29, 3×10-6 M fentanyl; -7.70 ± 0.28) in endothelium-denuded rat aorta (Fig. 1).
Treatment of the aorta with 5-MU (3×10-8, 10-7, 3×10-7 M) caused a parallel rightward shift (p < 0.01 versus no drug) in the phenylephrine concentration-response curve (ED50: no drug; -8.25 ± 0.19 versus 3×10-8 M 5-MU; -7.81 ± 0.13, 10-7 M 5-MU; -7.23 ± 0.26, 3×10-7 M 5-MU; -6.82 ± 0.15) in a concentration-dependent manner (Fig. 2A). Analysis of the data using an Arunlakshana and Schild plot for the antagonism of phenylephrine-induced contraction by 5-MU yielded a slope (1.21 ± 0.23) that was not significantly different from unity (Fig. 2B). The pA2 value for 5-MU was 7.71 ± 0.15 (Fig. 2B), which is approximately 10 times less than the reported affinity (9.3-8.4) for the α1A-adrenoceptor, suggesting that the α1A-adrenoceptor subtype does not play a main role in the phenylephrine-induced contraction of the rat aorta.8
BMY 7378 (3×10-9, 10-8, 3×10-8 M) produced a parallel rightward shift (p < 0.01 versus no drug) in the phenylephrine concentration-response curve (ED50: no drug; -8.26 ± 0.30 versus 3×10-9 M BMY 7378; -7.63 ± 0.19, 10-8 M BMY 7378; -7.32 ± 0.23, 3×10-8 M BMY 7378; -6.92×0.14) in a concentration-dependent manner (Fig. 3A). The Arunlakshana and Schild plot for antagonism of phenylephrine-induced contraction by BMY 7378 yielded a slope (0.87 ± 0.19) that was not significantly different from unity (Fig. 3B). The pA2 value for BMY 7378 was 8.99 ± 0.24 (Fig. 3B), which is close to the reported affinity (8.7-8.1) for the α1D-adrenoceptor, suggesting that the α1D-adrenoceptor plays a primary role in phenylephrine-induced contraction of the rat aorta.8
CEC (10-5 M) produced 72.9% inhibition of the first phenylephrine-induced maximal contraction (p < 0.0001 versus no drug) (Fig. 4), which suggests that phenylephrine-induced contraction in the rat aorta involves the CEC-sensitive α1-adrenoceptor subtype (α1B- and α1D-adrenoceptors).
Comparison with aortic rings not treated with fentanyl showed that fentanyl (10-6 M) significantly attenuated (p < 0.01 versus 5-MU alone) phenylephrine-induced contraction (ED50: 10-9 M 5-MU; -8.10 ± 0.24 versus 10-9 M 5-MU + 10-6 M fentanyl; -7.72 ± 0.24) in rings pretreated with 5-MU at a concentration of 10-9 M which is close to the reported affinity (9.3-8.4) for the α1A-adrenoceptor (Fig. 5).8
In rings pretreated with BMY 7378 at 3×10-9 M concentration which is close to the reported affinity (8.7-8.1) for the α1D-adrenoceptor, fentanyl (10-6 M) did not significantly alter phenylephrine-induced contraction as compared with rings not treated with fentanyl (Fig. 6).8
Fentanyl (3×10-6 M) had no effect on phenylephrine-induced contraction of rings pretreated with prazosin (3×10-9 M) (Fig. 7).

DISCUSSION

Despite widespread use of fentanyl in patients undergoing heart surgery, we believe that this is the first study to show that fentanyl attenuates phenylephrine-induced contraction by inhibiting the cellular signal transduction pathway involved in the α1D-adrenoceptor-mediated contraction of the rat aortic smooth muscle. The α1D-adrenoceptor exerts a great influence on modulation of contraction induced by phenylephrine in rat aortic smooth muscle.
Fentanyl attenuates phenylephrine-induced contraction in the canine pulmonary artery by binding to the α1B-adrenoceptor,6 and attenuates also the α1-adrenoceptor agonist (phenylephrine and norepinephrine)-induced dose-response curve by an alpha-adrenergic blocking action in isolated rabbit and rat aorta.4,5 Consistent with previous studies,4-6 fentanyl (10-6, 3×10-6 M) attenuated phenylephrine-induced contraction in the present study. In addition, prazosin completely abolished fentanyl-induced attenuation of contractile response induced by phenylephrine. These results suggest that fentanyl attenuates the phenylephrine dose-response curve by inhibiting α1-adrenoceptor-mediated contraction of rat aortic smooth muscle. The CR which was calculated as the ratio of the ED50 for phenylephrine in the presence or absence of fentanyl (10-6 M) was 2.52 ± 0.52, suggesting that the dose of phenylephrine required for the same magnitude of phenylephrine-induced contraction in the presence of fentanyl (10-6 M) is about 2.5 times higher than that in the absence of fentanyl. Fentanyl (100 ng/mL) induces a small, but statistically significant attenuation of the phenylephrine concentration-response curve in isolated endothelium-intact canine coronary arteries.14 However, the present study showed that fentanyl at a concentration of 3×10-7 M, which corresponds approximately to the plasma concentration (100 ng/mL) occurring in patients anesthetized with fentanyl for major surgery, had no effect on phenylephrine-induced contraction.3 The discrepancy in the results of the two studies may be ascribed to the difference in the vessel selected (endothelium-intact canine coronary artery versus endothelium-denuded rat aorta).
The estimated affinity of 5-MU for the α1A-adrenoceptor is approximately 10 times greater than that for the α1D-adrenoceptor and 100 times greater than that for the α1B-adrenoceptor.15,16 In the present in vitro study, the affinity of 5-MU estimated in the rat aorta (pA2 = 7.71 ± 0.15) was close to the value expected for an interaction with the α1D-adrenoceptor (7.80 ± 0.09, 7.91 ± 0.07) rather than the α1A-adrenoceptor (8.50 ± 0.09, 8.68 ± 0.09) or α1B-adrenoceptor (6.80 ± 0.13, 6.76 ± 0.17).15,16 BMY 7378 is a selective α1D-adrenoceptor antagonist, whose selectivity for α1D-adrenoceptor is 100 times greater than that for the α1A- or α1B-adrenoceptor.15,17 In this study, the estimated affinity of BMY 7378 was 8.99 ± 0.24, which is close to pKi values for the human recombinant α1D-adrenoceptor expressed in rat-1 fibroblast (9.39 ± 0.05) and the rat aorta (8.88 ± 0.10), demonstrating predominance of the α1D-adrenoceptor subtype.18 These results suggest that phenylephrine-induced contraction in rat aortic smooth muscle is primarily mediated by the α1D-adrenoceptor. The agreement between agonist potency and affinity for the α1D-adrenoceptor binding site shows that the α1D-adrenoceptor is responsible for mediating contraction of the rat aorta.19 The phenylephrine-induced contraction of the rat thoracic aorta is mainly mediated by the α1D-adrenoceptor.9,20,21 Consistent with previous studies,9,19-21 the present results suggest that the α1D-adrenoceptor is functionally important in mediating the phenylephrine-induced contraction of the rat aorta. Fentanyl (10-6 M) attenuated phenylephrine-induced contraction in rings when pretreated with 10-9 M 5-MU, but it did not significantly alter phenylephrine-induced contraction in rings pretreated with 3×10-9 M BMY 7378. Together with the present results suggesting that the α1D-adrenoceptor is mainly involved in phenylephrine-induced contraction, these results suggest that fentanyl attenuates phenylephrine-induced contraction by inhibiting α1D-adrenoceptor-mediated contraction in the rat aorta. However, to lessen overestimation that may occur from concentration of 5-methylurapidil (10-9 M) and BMY 7378 (3×10-9 M) adopted from previously reported pA2 values, competitive binding studies with radioisotope-tagged drugs are needed to examine the direct effect of fentanyl on α1-adrenoceptor subtypes (α1A and α1D).8 In a radioligand binding study involving 20-min incubation at 37℃, the α1B-adrenoceptor was preferentially (89 to 98%) inactivated by the irreversible α1B-adrenoceptor antagonist (10-4 M CEC), followed by α1D-adrenoceptor at 75 to 86% and α1A-adrenoceptor at 11 to 18%.22 Rat aortic rings exposed to CEC (5×10-6 M) show 20% reduction in phenylephrine-induced contraction.23 However, inhibition of contraction by pretreatment with 10-5 M CEC (20 min) was 72.9 ± 2.3% in this in vitro study. This different effect of CEC on phenylephrine-induced contraction may be ascribed to the difference in the concentration of CEC, incubation period and washing method with fresh Krebs solution. CEC has been used extensively as a tool to discriminate α1A-adrenoceptor (CEC-insensitive) from α1B- and α1D-adrenoceptors (CEC-sensitive).8 Pretreatment of rat aorta with CEC (3×10-5 M) showed 83.9% reduction of phenylephrine-induced contraction, which suggests that α1-adrenoceptor subtype of the rat aorta is CEC-sensitive subtype (α1B- and α1D-adrenoceptors).24 Based on the findings of current and previous studies, CEC-sensitive α1D-adrenoceptor appears to be involved in the phenylephrine-induced contraction of the rat aorta.8,24 Interestingly, α1-adrenoceptors seem to be regulated by crosstalk between G-protein-coupled receptors and subsequent signaling cascades.25 Further investigation is needed in order to determine the effect of fentanyl on G-protein, phospholipase C, the coupling processes, inositol 1,4,5-triphosphate and diacylglycerol, since all these factors are involved in the cellular signal transduction pathway for α1D-adrenoceptor-mediated phenylephrine-induced contraction.
Fentanyl (2.97×10-6 M) attenuates the nitric oxide-mediated relaxation induced by acetylcholine,26 and produces hypotension by inhibiting central sympathetic outflow in intact dogs anesthetized with enflurane.27 Previous studies have shown that fentanyl has no effect on myocardial contractility at a clinical dose and increases myocardial contractile force at supraclinical doses.28,29 According to the findings described above, the net hemodynamic effect of fentanyl in vivo is a composite of the effect of fentanyl on blood vessel, central sympathetic activity and the heart.26-29 Any clinical implications of fentanyl on regional hemodynamics must be tempered by the fact that a large conduit artery, the aorta, was used in this in vitro experiment, whereas the resistance vessels with the arterioles of a diameter of 100-300 µm control most organ blood flow.30 Even with these limitations, since 3×10-7 M fentanyl (plasma fentanyl concentration 100 µg/mL) did not alter phenylephrine-induced contraction, the indirect mechanism for vasodilation, which is mediated by decreased central sympathetic outflow induced by fentanyl, might be involved in the hypotension observed in the previous in vivo studies.1-3,27
Fentanyl significantly attenuated phenylephrine-induced contraction at concentrations of 10-6 and 3×10-6 M, which are higher than clinically relevant concentration (9.52×10-8 M).3 However, the rapid redistribution of fentanyl (octanol: water partition coefficient = 813) to lipid-rich tissue may create a discrepancy between the serum concentration and actual tissue concentration.31 Because cerebrospinal fluid contains very little protein in comparison to plasma, the average concentration of active fentanyl in cerebrospinal fluid is approximately 46% of the total plasma fentanyl concentration, which is more than twice the free fraction of plasma fentanyl.32,33 Small changes in the amount or binding capacity of proteins in certain pathologic conditions (example: liver disease, hemodilution, hypoproteinemia) could result in an increase in the free fraction of fentanyl. Taking the above findings into consideration, the 10-6 M concentration of fentanyl required for an inhibitory effect on phenylephrine-induced contraction might be the concentration encountered in clinical settings.31-33
In conclusion, the present results suggest that fentanyl at supraclinical dose (10-6 M) attenuates phenylephrine-induced contraction of rat aortic smooth muscle by inhibiting the pathway involved in the α1D-adrenoceptor-mediated contraction. In addition, the α1D-adrenoceptor is functionally important in mediating phenylephrine-induced contraction of isolated rat aorta.

Figures and Tables

Fig. 1
Effect of fentanyl on the phenylephrine dose-response curve in endothelium-denuded rat aorta. Fentanyl (10-6, 3×10-6 M) produced a significant rightward shift (ED50: *p < 0.05 versus no drug) in the phenylephrine dose-response curve. Data are shown as mean ± SD and expressed as the percentage of maximal contraction induced by isotonic 60 mM KCl (isotonic 60 mM KCl-induced contraction: 100% = 2.62 ± 0.39 g [n = 7], 100% = 2.65 ± 0.33 g [n = 5], 100% = 2.67 ± 0.37 g [n = 7] and 100% = 2.22 ± 0.29 g [n = 6] for the rings not treated with fentanyl, the fentanyl [3×10-7 M], [10-6 M] and [3×10-6 M] pretreated rings, respectively).
ymj-50-414-g001
Fig. 2
(A) Effect of 5-methylurapidil (5-MU) on phenylephrine doe-response curve. 5-MU (3×10-8, 10-7, 3×10-7 M) produced a parallel rightward shift (ED50: *p < 0.01 versus no drug, †p < 0.001 versus 3×10-8 M 5-MU, ‡p < 0.05 versus 10-7 M 5-MU) in the phenylephrine dose-response curve in a concentration-dependent manner. Data are shown as mean ± SD and expressed as the percentage of maximal contraction induced by isotonic 60 mM KCl (isotonic 60 mM KCl-induced contraction: 100% = 3.30 ± 0.84 g [n = 5], 100% = 2.82 ± 0.75 g [n = 5], 100% = 2.74 ± 0.52 g [n = 5] and 100% = 2.38 ± 0.71 g [n = 5] for the rings not treated with 5-MU, the 5-MU [3×10-8 M], [10-7 M] and [3×10-7 M] pretreated rings, respectively). (B) A Schild plot was constructed with the concentration ratio (CR: ED50 in the presence and absence of 5-MU) for individual experiments. The slope of the Schild plot for 5-MU was 1.21 ± 0.23 (r2 = 0.69), and the concentration (-log M) of 5-MU necessary to displace the phenylephrine concentration-response curve by twofold was 7.71 ± 0.15.
ymj-50-414-g002
Fig. 3
(A) Effect of BMY 7378 on phenylephrine does-response curve. BMY 7378 (3×10-9, 10-8, 3×10-8 M) produced a parallel rightward shift (ED50: *p < 0.01 versus no drug, †p < 0.001 versus 3 ×10-9 M BMY 7378, ‡p < 0.001 versus 10-8 M BMY 7378) in the phenylephrine dose-response curve in a concentration-dependent manner. Data are shown as mean ± SD and expressed as the percentage of maximal contraction induced by isotonic 60 mM KCl (isotonic 60 mM KCl-induced contraction: 100% = 3.03 ± 0.81 g [n = 5], 100% = 2.90 ± 0.31 g [n = 5], 100% = 2.47 ± 0.66 g [n = 5] and 100% = 2.34 ± 0.26 g [n = 5] for the rings not treated with BMY 7378, the BMY 7378 [3×10-9 M], [10-8 M] and [3×10-8 M] pretreated rings, respectively). (B) A Schild plot was constructed with the concentration ratio (CR: ED50 in the presence and absence of BMY 7378) for individual experiments. The slope of the Schild plot for BMY 7378 was 0.87 ± 0.19 (r2 = 0.62), and the concentration (-log M) of BMY 7378 necessary to displace the phenylephrine concentration-response curve by twofold was 8.99 ± 0.24.
ymj-50-414-g003
Fig. 4
Effect of chloroethylclonidine (CEC) on phenylephrine dose-response curve in endothelium-denuded rat aorta. The first phenylephrine dose-response curves were obtained before (no drug) exposure to 10-5 M CEC. After aortic rings were pretreated with 10-5 M CEC for 20 min and washed intensively, second dose-response curves for phenylephrine were obtained. CEC (10-5 M) inhibited maximal contraction induced by phenylephrine (*p < 0.0001 versus no drug). Data are shown as mean ± SD and expressed as the percentage of the first phenylephrine-induced maximal contraction (phenylephrine-induced maximal contraction: 100% = 3.9 ± 0.16 g [n = 4] for the rings with no drug).
ymj-50-414-g004
Fig. 5
Effect of 10-6 M fentanyl on phenylephrine dose-response curve in rings pretreated with 10-9 M 5-methylurapidil. Fentanyl (10-6 M) attenuated (ED50: *p < 0.01 versus 10-9 M 5-methylurapidil alone) phenylephrine-induced contraction compared with rings pretreated with 10-9 M 5-methylurapidil alone. Data are shown as mean ± SD and expressed as the percentage of maximal contraction induced by isotonic 60 mM KCl (isotonic 60 mM KCl-induced contraction: 100% = 2.71 ± 0.68 g [n = 9] and 100% = 2.98 ± 0.43 g [n = 9] for the rings not treated with fentanyl and the fentanyl [10-6 M] pretreated rings, respectively).
ymj-50-414-g005
Fig. 6
Effect of 10-6 M fentanyl on the phenylephrine dose-response curve in rings pretreated with 3×10-9 M BMY 7378. Fentanyl (10-6 M) did not significantly alter pheny lephrine-induced contraction compared with rings pretreated with 3×10-9 M BMY 7378 alone. Data are shown as mean ± SD and expressed as the percentage of maximal contraction induced by isotonic 60 mM KCl (isotonic 60 mM KCl-induced contraction: 100% = 2.89 ± 0.33 g [n = 7] and 100% = 2.72 ± 0.36 g [n = 7] for the rings not treated with fentanyl and the fentanyl [10-6 M] pretreated rings, respectively).
ymj-50-414-g006
Fig. 7
Effect of fentanyl on the phenylephrine dose-response curve in rings pretreated with 3×10-9 M prazosin. Fentanyl (3×10-6 M) had no effect on the phenylephrine dose-response curve in the rings pretreated with 3×10-9 M prazosin. Data are shown as mean ± SD and expressed as the percentage of maximal contraction induced by isotonic 60 mM KCl (isotonic 60 mM KCl-induced contraction: 100% = 3.06 ± 0.32 g [n = 7] and 100% = 3.03 ± 0.55 g [n = 7] for the rings not treated with fentanyl and the fentanyl [3×10-6 M] pretreated rings, respectively).
ymj-50-414-g007

References

1. Graves CL, Downs NH, Browne AB. Cardiovascular effects of minimal analgesic quantities of innovar, fentanyl, and droperidol in man. Anesth Analg. 1975. 54:15–23.
2. Freye E. Cardiovascular effects of high dosages of fentanyl, meperidine, and naloxone in dogs. Anesth Analg. 1974. 53:40–47.
3. Wynands JE, Townsend GE, Wong P, Whalley DG, Srikant CB, Patel YC. Blood pressure response and plasma fentanyl concentrations during high- and very high-dose fentanyl anesthesia for coronary artery surgery. Anesth Analg. 1983. 62:661–665.
4. Toda N, Hatano Y. Alpha-adrenergic blocking action of fentanyl on the isolated aorta of the rabbit. Anesthesiology. 1977. 46:411–416.
crossref
5. Karasawa F, Iwanou V, Moulds RF. Effects of fentanyl on the rat aorta are mediated by alpha-adrenoceptors rather than by the endothelium. Br J Anaesth. 1993. 71:877–880.
6. Sohn JT, Ding X, McCune DF, Perez DM, Murray PA. Fentanyl attenuates alpha1B-adrenoceptor-mediated pulmonary artery contraction. Anesthesiology. 2005. 103:327–334.
crossref
7. Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ, et al. International Union of Pharmacology. X. Recommendation for nomenclature of alpha1-adrenoceptors: consensus update. Pharmacol Rev. 1995. 47:267–270.
8. Vargas HM, Gorman AJ. Vascular alpha-1 adrenergic receptor subtypes in the regulation of arterial pressure. Life Sci. 1995. 57:2291–2308.
crossref
9. Asbún-Bojalil J, Castillo EF, Escalante BA, Castillo C. Does segmental difference in alpha 1-adrenoceptor subtype explain contractile difference in rat abdominal and thoracic aorta? Vascul Pharmacol. 2002. 38:169–175.
crossref
10. Arévalo-León LE, Gallardo-Ortíz IA, Urquiza-Marín H, Villalobos-Molina R. Evidence for the role of alpha1D- and alpha1A-adrenoceptors in contraction of the rat mesenteric artery. Vascul Pharmacol. 2003. 40:91–96.
crossref
11. Errasti AE, Velo MP, Torres RM, Sardi SP, Rothlin RP. Characterization of alpha1-adrenoceptor subtypes mediating vasoconstriction in human umbilical vein. Br J Pharmacol. 1999. 126:437–442.
crossref
12. Low AM, Lu-Chao H, Wang YF, Brown RD, Kwan CY, Daniel EE. Pharmacological and immunocytochemical characterization of subtypes of alpha-1 adrenoceptors in dog aorta. J Pharmacol Exp Ther. 1998. 285:894–901.
13. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959. 14:48–58.
14. Blaise GA, Witzeling TM, Sill JC, Vinay P, Vanhoutte PM. Fentanyl is devoid of major effects on coronary vasoreactivity and myocardial metabolism in experimental animals. Anesthesiology. 1990. 72:535–541.
15. Kenny BA, Chalmers DH, Philpott PC, Naylor AM. Characterization of an alpha1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br J Pharmacol. 1995. 115:981–986.
16. Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, et al. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994. 45:703–708.
17. Goetz AS, King HK, Ward SDL, True TA, Rimele TJ, Saussy DL Jr. BMY 7378 is a selective antagonist of the D subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1995. 272:R5–R6.
18. Saussy DL Jr, Goetz AS, Queen KL, King HK, Lutz MW, Rimele TJ. Structure activity relationships of a series of buspirone analogs at alpha 1 adrenoceptor: further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtypes. J Pharmacol Exp Ther. 1996. 278:136–144.
19. Buckner SA, Oheim KW, Morse PA, Knepper SM, Hancock AA. Alpha 1-adrenoceptor-induced contractility in rat aorta is mediated by the alpha 1 D subtype. Eur J Pharmacol. 1996. 297:241–248.
crossref
20. Hussain MB, Marshall I. Characterization of alpha 1-adrenoceptor subtypes mediating contractions to phenylephrine in rat thoracic aorta, mesenteric artery and pulmonary artery. Br J Pharmacol. 1997. 122:849–858.
crossref
21. Deng XF, Chemtob S, Varma DR. Characterization of alpha 1D-adrenoceptor subtype in rat myocardium, aorta and other tissues. Br J Pharmacol. 1996. 119:269–276.
crossref
22. Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, et al. Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995. 272:134–142.
23. Fagura MS, Lydford SJ, Dougall IG. Pharmacological classification of alpha 1-adrenoceptors mediating contractions of rabbit isolated ear artery: comparison with rat isolated thoracic aorta. Br J Pharmacol. 1997. 120:247–258.
crossref
24. Maruyama K, Suzuki M, Tsuchiya M, Makara Y, Hattori K, Ohnuki T, et al. Discrimination of alpha 1-adrenoceptor subtypes in rat aorta and prostate. Pharmacology. 1998. 57:88–95.
crossref
25. Michelotti GA, Price DT, Schwinn DA. Alpha 1-adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther. 2000. 88:281–309.
crossref
26. Sohn JT, Ok SH, Kim HJ, Moon SH, Shin IW, Lee HK, et al. Inhibitory effect of fentanyl on acetylcholine-induced relaxation in rat aorta. Anesthesiology. 2004. 101:89–96.
crossref
27. Flacke JW, Davis LJ, Flacke WE, Bloor BC, Van Etten AP. Effects of fentanyl and diazepam in dogs deprived of autonomic tone. Anesth Analg. 1985. 64:1053–1059.
crossref
28. Kawakubo A, Fujigaki T, Uresino H, Zang S, Sumikawa K. Comparative effects of etomidate, ketamine, propofol, and fentanyl on myocardial contractility in dogs. J Anesth. 1999. 13:77–82.
crossref
29. Suzer O, Suzer A, Aykac Z, Ozuner Z. Direct cardiac effects in isolated perfused rat hearts measured at increasing concentrations of morphine, alfentanil, fentanyl, ketamine, etomidate, thiopentone, midazolam and propofol. Eur J Anaesthesiol. 1998. 15:480–485.
crossref
30. Christensen KL, Mulvany MJ. Location of resistance arteries. J Vasc Res. 2001. 38:1–12.
crossref
31. Etches RC, Sandler AN, Daley MD. Respiratory depression and spinal opioids. Can J Anaesth. 1989. 36:165–185.
crossref
32. Artru AA. Cottrell JE, Smith DS, editors. Cerebrospinal fluid. Anesthesia and Neurosurgery. 2001. 4th ed. Philadelphia: Mosby;84–85.
crossref
33. Hug CC Jr, Murphy MR. Fentanyl disposition in cerebrospinal fluid and plasma and its relationship to ventilatory depression in the dog. Anesthesiology. 1979. 50:342–349.
crossref
TOOLS
Similar articles